Category: Treatment
What Uveal Melanoma Patients Need to Know about KIMMTRAK
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 18 July 2022 In Science, Treatment
You may have heard of KIMMTRAK, a new therapy that recently earned FDA approval for the treatment of metastatic or unresectable uveal melanoma. Uveal melanoma, also called ocular melanoma, is a rare melanoma subtype that affects about 2,500 people each year in the United States. KIMMTRAK is the first drug to earn FDA approval to treat these patients.
What Melanoma Patients Need to Know about Opdualag
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 May 2022 In Science, Treatment
You may have heard of Opdualag, a new therapy that recently earned FDA approval for advanced melanoma. Opdualag, which combines two different immunotherapies into one medicine, is earning attention as an effective – and more easily tolerated – combination therapy.
MRA Announces $13 Million in Grants to Advance Melanoma Prevention, Detection & Treatment
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 19 May 2022 In News, Prevention, Science, Treatment
Coinciding with Melanoma Awareness Month, the Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research, today announced funding for 27 research grants totaling $13,046,774 to support new research aimed at advancing melanoma prevention, diagnosis and treatment.
Dr. Gary Deng & The Wellness Principles
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 9 May 2022 In Allies & Partnerships, Prevention, Treatment
Gary Deng, MD, PhD – an integrative medicine specialist at Memorial Sloan Kettering Cancer Center – knows this firsthand. And now, for the first time, Dr. Deng is sharing his unique and highly respected wellness approach with everyone through his upcoming book, The Wellness Principles – Cooking for a Healthy Life.
Unlocking the Potential of Localized Treatments By Better Understanding Treatment Response
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 23 March 2022 In News, Science, Treatment
It’s easy to think of melanoma – or any cancer – in black and white terms. You have it or you don’t, it responds or it’s resistant to treatment, or it grows or it shrinks. However, like most things, the reality is far more complex.
MRA Applauds Approval of Relatlimab + Nivolumab for the Treatment of Advanced Melanoma
18 March 2022 In News, Science, Treatment
The Melanoma Research Alliance (MRA) welcomed the news today that the U.S. Food & Drug Administration (FDA) has approved Opdualag™, Bristol-Myers Squibb’s new combination immunotherapy for the treatment of advanced melanoma.
Recordings from MRA's 2022 Patient Forum
16 March 2022 In Allies & Partnerships, Events, Melanoma Stories, News, Policy, Prevention, Science, Treatment
MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, 2022, brought together hundreds of melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provided networking opportunities across the melanoma community.
New Research Says Immunotherapy Should be First-Line Therapy for Patients with BRAF-Mutant Melanoma
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 2 February 2022 In News, Science, Treatment
While all patients with advanced melanoma can be treated with checkpoint immunotherapies, patients with tumors containing the BRAF mutation can also be treated with targeted therapies. However, until now, doctors have had little prospective data to determine which treatment approach should be started first. A new study led by Dr. Michael Atkins provides practice-changing insight.
MRA Celebrates Approval of Tebentafusp - First Drug for Metastatic Uveal Melanoma
By Cody Barnett, MPH, MRA Senior Director of Communications & Patient Engagement | 26 January 2022 In News, Treatment
The Melanoma Research Alliance (MRA), the largest non-profit funder of melanoma research worldwide, applauds the U.S. Food and Drug Administration (FDA) decision to approve the first-ever therapy for metastatic or unresectable uveal melanoma.
Registration Now Open for March 9 Patient Forum!
11 January 2022 In Allies & Partnerships, Events, News, Policy, Prevention, Science, Treatment
MRA’s Melanoma Exchange Patient Forum, held in-person in Washington DC and virtually on March 9, will bring together melanoma patients, survivors, advocates, and their loved ones to provide lay-friendly, state-of-the-science education, promote collaboration, and provide networking opportunities across the melanoma community.